Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 156

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 156
---
217 pending patent applications, including six allowed patent applications, and four
PCT applications.

Pursuant to an Intellectual
Property Purchase Agreement dated February 2, 2016, we acquired from Althera Medical Ltd. a patent portfolio which now totals 80 patents,
including some patent applications whose prosecution was completed following our acquisition. These patents were all assigned to us and
are recorded in our name. The patents relate primarily to a device, method of treatment, or method of production of the Alpha DaRT product
itself, specifically, to intratumoral diffusing alpha-emitter radiation therapy wherein a probe is loaded with radioisotopes which undergo
a process of alpha-emitting radioactive decay solely in proximity to and/or within a tumor. These patents include three U. S. patents,
one Canadian patent, three Japanese patents, one Chinese patent, one Hong Kong patent, two European patents each validated in 30 European
countries, two Korean patents, three U. K. patents, three French patents, and three German patents. The three issued patents in the United
States are expected to expire between 2025 and 2029, without accounting for any potential patent term adjustments or extensions or other
forms of exclusivity.

We have nine issued patents,
and eight pending patent applications, of which one patent application is allowed, relating to the use of a polymer allowing daughter
atoms to escape the source and penetrate the tumor where they emit alpha particles by diffusion. This increases the percentage of daughter
radionuclides that reach the tumor. The nine issued patents have been issued in the U. S., Australia, Japan, India, Korea, South Africa,
the African Regional Intellectual Property Organization (ARIPO), Russia, and Singapore. The foregoing patent applications are pending
in the U. S., Europe, Japan, Canada, China, Mexico, Hong Kong, of which the U. S. continuation patent application has been allowed. These
patents or patents issuing from the pending applications will begin to expire in 2038, exclusive of possible patent term adjustments or
extensions or other forms of exclusivity.

We have eight issued patents,
and eight pending patent applications, relating to the potential controlled release of a certain amount of Radium-224 from the Alpha DaRT
source into the tumor. The eight issued patents have been issued in the U. S., Australia, South Africa, India, Korea, China, ARIPO, and
Hong Kong. Eight patent applications are pending in Europe, Japan,